{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:11:40Z","timestamp":1785435100053,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.eimce.2022.07.006","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T07:21:52Z","timestamp":1658820112000},"page":"301-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The new generation of messenger RNA (mRNA) vaccines against influenza"],"prefix":"10.1016","volume":"41","author":[{"given":"Jordi","family":"Reina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2022.07.006_bib0005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eimc.2015.06.011","article-title":"Vacunaci\u00f3n antigripal. Efectividad de las vacunas actuales y retos de futuro","volume":"33","author":"Ortiz de Lejarazu","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimce.2022.07.006_bib0010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14760584.2017.1355245","article-title":"Mechanism of action of mRNA-based vaccines","volume":"16","author":"Lavarone","year":"2017","journal-title":"Exp Rev Vaccines"},{"key":"10.1016\/j.eimce.2022.07.006_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.608460","article-title":"RNA vaccines: a suitable platform for tackling emerging pandemics?","volume":"11","author":"Sandbrink","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.eimce.2022.07.006_bib0020","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.eimce.2022.07.006_bib0025","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.eimce.2022.07.006_bib0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/vaccines6020020","article-title":"New kids on the block: RNA-based influenza virus vaccines","volume":"6","author":"Scorza","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.eimce.2022.07.006_bib0035","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3390\/microorganisms8111745","article-title":"New technologies for influenza vaccines","volume":"8","author":"Rockman","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.eimce.2022.07.006_bib0040","first-page":"e52","article-title":"Rapidly producen SAM vaccine against H7N9 influenza is immunogenic in mice","volume":"2","author":"Hekele","year":"2013","journal-title":"Emer Microb Infect"},{"key":"10.1016\/j.eimce.2022.07.006_bib0045","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/JVI.01786-15","article-title":"Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin","volume":"90","author":"Brazzoli","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.eimce.2022.07.006_bib0050","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.2147\/IJN.S39810","article-title":"Development of nucleica cid vaccines: use of self-amplifying RNA in lipid nanoparticles","volume":"9","author":"Rodriguez-Gascon","year":"2014","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.eimce.2022.07.006_bib0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/vaccines8010123","article-title":"mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice","volume":"8","author":"Zhuang","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.eimce.2022.07.006_bib0060","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.eimce.2022.07.006_bib0065","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nature Biotech"},{"key":"10.1016\/j.eimce.2022.07.006_bib0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-017-0032-6","article-title":"Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines","volume":"2","author":"Lutz","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.eimce.2022.07.006_bib0075","first-page":"3361","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.eimce.2022.07.006_bib0080","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.eimce.2022.07.006_bib0085","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.eimce.2022.07.006_bib0090","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in Rhesus macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.eimce.2022.07.006_bib0095","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3389\/fimmu.2017.01539","article-title":"Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+PD-1+T CXCR3+ T folicular helper cells","volume":"8","author":"Lindgren","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.eimce.2022.07.006_bib0100","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.eimce.2022.07.006_bib0105","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/319857","article-title":"Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus and tickborne encephalitis virus","volume":"183","author":"Fleeton","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimce.2022.07.006_bib0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161193","article-title":"Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challende","volume":"11","author":"Magini","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.eimce.2022.07.006_bib0115","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.eimce.2022.07.006_bib0120","unstructured":"World Health Organization. WHO preferred product characteristics for next-generation influenza vaccines. [Accessed 20 April 2021]. Available from: http:\/\/who.int\/immunization\/documents\/ISBN_978-92-4-151246-6\/en."},{"key":"10.1016\/j.eimce.2022.07.006_bib0125","first-page":"8","article-title":"Better, faster, stronger: mRNA vaccines shown promise for influenza vaccination in older adults","author":"Bartley","year":"2021","journal-title":"Immunol Invest"}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X22001666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X22001666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:01:09Z","timestamp":1762866069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X22001666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2529993X22001666"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2022.07.006","relation":{},"ISSN":["2529-993X"],"issn-type":[{"value":"2529-993X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The new generation of messenger RNA (mRNA) vaccines against influenza","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2022.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2021.07.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}